CT
Therapeutic Areas
Gibson Oncology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LMP744 | Glioblastoma | Phase 2 |
| LMP400 | Solid Tumors, Lymphomas, PTEN-deficient tumors | Phase 1 |
| LMP776 | Solid Tumors, Lymphomas | Phase 1 |
| Aza Indenoisoquinolines | Oncology | Pre-clinical |
Leadership Team at Gibson Oncology
MC
Mark C. Rogers, MD, MBA
Founder and Executive Chair
RB
Randall B. Riggs
President and Chief Executive Officer
TC
Theodore C Solomon
Founder and Chief Financial Officer
EL
Elizabeth London Rogers, MD
Founder and Chief Operations Officer
MS
Mark S. Cushman, PhD., PharmD
Founder and Chief Scientific Officer